{
    "clinical_study": {
        "@rank": "161466", 
        "arm_group": [
            {
                "arm_group_label": "Anlotinib hydrochloric capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "Anlotinib hydrochloric capsule 12mg QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
            }, 
            {
                "arm_group_label": "Placebo Capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent"
            }
        ], 
        "brief_summary": {
            "textblock": "Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug\n      Administration\uff08SFDA:2011L00661\uff09 which was researched by Jiangsu Chia-tai Tianqing\n      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with\n      multi-targets, especially for VEGFR2\u3001VEGFR3\u3001PDGFR\u03b2 and c-Kit. It has the obvious resistance\n      to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of\n      andvanced non-small cell lung cancer who failed two lines of chemotherapy"
        }, 
        "brief_title": "Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. pathology diagnosed with advanced NSCL with measurable lesions;\n\n          2. Have failed for 2 lines of chemotherapy;\n\n          3. 18-70years,ECOG PS:0-2,Life expectancy of more than 3 months;\n\n          4. Other cytotoxic drugs,radiation therapy,or surgery\u22654 weeks;\n\n          5. main organs function is normal;\n\n          6. must be agreed to take contraceptive measures during the study and within 6 months\n             after end.\n\n        Exclusion Criteria:\n\n          1. SCLC(including mixed with NSCLC);\n\n          2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;\n\n          3. patients failed to use the anti-tumor angiogenesis therapy;\n\n          4. patients has many influence factors toward oral medications ;\n\n          5. Brain metastases patients accompanied by symptoms or symptom control for less than\n             two months;\n\n          6. patients with severe and failed to controlled diseases,including: suboptimal blood\n             pressure control;suffering from myocardial ischemia or above grade I myocardial\n             infarction, arrhythmias and Class I heart failure;activity or failure to control\n             severe infections;liver disease such as cirrhosis, decompensated liver disease,\n             chronic active hepatitis;poorly controlled diabetes (FBG)>10mmol/L);urine\n             protein\u2265++,etc.\n\n          7. patients failed to heal wounds or fractures for Long-term;\n\n          8. 4 weeks before enrollment, patients appeared NCI CTC AE grading >1 pulmonary\n             hemorrhage; 4 weeks before enrollment, patients who  appeared NCI CTC AE grade> 2\n             have other parts of the bleeding; patients has a tendency to bleed (eg active peptic\n             ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin,\n             heparin or its analogues;\n\n          9. patients occurred venous thromboembolic events within 6 months;\n\n         10. patients has HIV-positive or organ transplantation;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924195", 
            "org_study_id": "ALTN-03-II"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anlotinib hydrochloric capsule", 
                "description": "Anlotinib hydrochloric capsule 12mg QD po. continue for tow weeks then stop one week", 
                "intervention_name": "Anlotinib hydrochloric capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Capsule", 
                "description": "Placebo capsule QD po. continue for tow weeks then stop one week", 
                "intervention_name": "Placebo Capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "lung", 
            "Anlotinib", 
            "AL3818", 
            "NSCLC", 
            "Cancer"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Yuan kai Shi, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Hong yu Wang, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bao lan Li, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "101149"
                    }, 
                    "name": "Beijing chest hospital\uff0ccapital medical university"
                }, 
                "investigator": {
                    "last_name": "Ying Hu, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Guoming Wu, Doctor"
                }, 
                "contact_backup": {
                    "last_name": "Kexiong Lin, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400037"
                    }, 
                    "name": "Xinqiao Hospital, Third Military Medical University"
                }, 
                "investigator": [
                    {
                        "last_name": "Guoming Wu, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kexiong Lin, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yi Luo, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410013"
                    }, 
                    "name": "Hunan Province Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Yi Luo, doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jianan Huang, doctor"
                }, 
                "contact_backup": {
                    "last_name": "Junhong Jiang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "215006"
                    }, 
                    "name": "The First Affiliated Hospital of Suzhou University"
                }, 
                "investigator": {
                    "last_name": "Jianan Huang, doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ying Cheng, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin", 
                        "zip": "130000"
                    }, 
                    "name": "Jilin province tumor hospital"
                }, 
                "investigator": {
                    "last_name": "Xian hong Liu, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhehai Wang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250117"
                    }, 
                    "name": "Shandong Province Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Zhehai Wang, doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bao hui Han, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200000"
                    }, 
                    "name": "Chest hospital affiliated to Shanghai jiaotong university"
                }, 
                "investigator": {
                    "last_name": "Zhi qiang Gao, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Qiang Li, doctor"
                }, 
                "contact_backup": {
                    "last_name": "Yiping Han, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200433"
                    }, 
                    "name": "Shanghai Changhai Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Qiang Li, doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yiping Han, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "You Lu, doctor"
                }, 
                "contact_backup": {
                    "last_name": "Li Ren, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "West China Hospital,Sichuan University"
                }, 
                "investigator": [
                    {
                        "last_name": "You Lu, doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Li Ren, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kai Li, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "Tianjin Medical University Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Kai Li, doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jian ying Zhou, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "The first affiliated hospital,zhejiang university"
                }, 
                "investigator": {
                    "last_name": "Zhi jie Pan, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yiping Zhang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310022"
                    }, 
                    "name": "Zhejiang Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Yiping Zhang, doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818)Hydrochloric Capsule as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer", 
        "overall_contact": {
            "email": "xkyyhan@gmail.com", 
            "last_name": "Bao hui Han, Professor"
        }, 
        "overall_official": {
            "affiliation": "Chest hospital affiliated to Shanghai jiaotong university", 
            "last_name": "Bao hui Han, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles. Refer to recist 1.1.", 
            "measure": "enhanced CT/MRI scan", 
            "safety_issue": "No", 
            "time_frame": "each 42 days up to disease progression"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924195"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "contain Serious Adverse Event To evaluate the safety of Anlotinib by CTC AE 4.0", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "each 21 days up to intolerance the toxicity(or PD)"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}